Cherry Brian N 4

What Happened

• Brian N. Cherry, a director of Atara Biotherapeutics (ATRA), was granted 24,000 restricted stock units (RSUs) on June 11, 2026. The Form 4 reports an acquisition at $0.00 per share (total dollar amount listed as $0), which reflects that no cash was paid at grant. This is a compensation award, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-11 (Form 4 filed 2026-06-15; filing appears timely).
• Transaction type/code: Award/Grant (A).
• Shares/units granted: 24,000 RSUs at $0.00 per share (total $0 reported).
• Shares owned after transaction: Not specified in the filing.
• Footnote: RSUs vest 1/3 on each of the first, second and third anniversaries of June 11, 2026, subject to Mr. Cherry’s continuous service.
• No 10b5-1, tax withholding, or sale reported in this filing.

Context

• RSUs are a form of equity compensation that convert to common shares as they vest; because these units were granted rather than purchased, they do not represent an immediate cash outlay or sale. Such awards are commonly part of director compensation and do not by themselves signal a buying or selling preference.